Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 20;38(29):5470-5485.
doi: 10.1002/sim.8371. Epub 2019 Oct 17.

Multi-stage enrichment and basket trial designs with population selection

Wen Li  1 , Jing Zhao  1 , Xiaoyun Li  1 , Cong Chen  1 , Robert A Beckman  2
Affiliations

Multi-stage enrichment and basket trial designs with population selection

Wen Li et al. Stat Med. .

Abstract

As biomarker information from early-phase trials can be unreliable due to high variability, it is logical to take a prospective two-stage approach when designing a late-phase confirmatory trial, ie, refining the target population at the first stage and performing the hypothesis testing at the second stage. The use of a reliable intermediate endpoint at the first stage can further improve the trial efficiency from both time and cost perspectives. Nevertheless, there are needs for expanding such two-stage confirmatory designs to more stages for monitoring efficacy on the refined population. There is limited literature on this matter, particularly for two popular designs with population selection midway, ie, the biomarker enrichment design and the basket design. In this manuscript, we focus on these two popular designs and discuss how to implement the interim efficacy analyses after population refinement while controlling type I error. Power and stopping probability are also explored for the two designs.

Keywords: O'Brien-Fleming boundary; ascending design; basket design; biomarker adaptive enrichment; population selection.

PubMed Disclaimer

References

REFERENCES

    1. Stallard N, Todd S. Seamless phase II/III design. Stat Methods Med Res. 2010;20(6):623-634. https://doi.org/10.1177/0962280210379035
    1. Magnusson BP, Turnbull BW. Group sequential enrichment design incorporating subgroup selection. Statist Med. 2013;32(16):2695-2714. https://doi.org/10.1002/sim.5738
    1. Mehta C, Schafer H, Daniel H, Irle S. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints. Statist Med. 2014;33(26):4515-4531. https://doi.org/10.1002/sim.6272
    1. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharm Stat. 2011;10:347-356. https://doi.org/10.1002/pst.472
    1. Todd S, Stallard N. A new clinical trial design combining phases 2 and 3: sequential designs with treatment selection and a change of endpoint. Drug Inf J. 2005;39:109-118.

MeSH terms

LinkOut - more resources